Bryan, Garnier & Co publishes a new Independent Research Update on AstraZeneca
BUY, FV 3730p vs. 3680p
Step by Step
In the space of a couple of weeks AstraZeneca has announced two deals which illustrate fairly well how business development (BD) should strengthen its key therapeutic franchises. First with Omthera Pharmaceuticals and then with Pearl Therapeutics, AstraZeneca has acquired late-stage compounds in cardio-metabolism and respiratory respectively which fuel the pipeline very effectively. Now the piece of the puzzle that is still missing is to make 2013 the trough year.
Full report available to subscribers
Please contact email@example.com